AI-Designed Base Editor Secures Funding
nathanbenaich · x · 2026-07-10
Profluent Bio is partnering with GEMMABio and has received ARPA-H funding to develop AI-designed base editors for two rare liver diseases. The post emphasizes that such efforts are shifting rare disease treatment from a "one drug for one disease" model to a scalable platform solution.
More from Companies & People
- Moonshot AI reportedly targets a $50B round ahead of Hong Kong listing — ctjlewis · 2026-07-22
- Annotated transcript of a Claude Code team interview is now available — trq212 · 2026-07-22
- AI industry astroturfing roundup tracks the sector’s fake-grassroots problem — ShakeelHashim · 2026-07-22
- Enterprise AI’s real value is in agentic workflows, not generic chatbots — irfan__77 · 2026-07-22
- Tesla expands Robotaxi rides to seven areas, including new Orlando and Tampa zones — elonmusk · 2026-07-22
- $5.3B Healthcare AI Leader: Domain Expertise Beats Tech — elizabeth · 2026-07-22